Thus, who senses (TAM/MDSC vs DC/NK/B), what is sensed (Gal-9 vs β-glucan and its form), and where (tumor type: PDA/GC/CRC/lung/glioma vs liver or β-glucan-primable settings) together seem to forecast whether Dectin-1 tilts toward tumor promotion or tumor control (Figure 2). The gene discussed is CLEC7A; the disease is Patent ductus arteriosus.